# US 2024/0200009 A1 · System and methods for immune cells expansion and activation in large scale

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200009 A1
- Document ID: US20240200009A1
- Status: Published application
- Kind: A1
- Application number: 18/593,869
- Filed: 2024-03-02
- Published: 2024-06-20
- Earliest claimed: 2022-05-23
- Assignees: Pluri Biotech Ltd.
- Applicants: Pluri Biotech Ltd.
- Inventors: Lior RAVIV; Shirley BACHAR; Dorina ROBERMAN
- Web page: https://patentgrep.com/patent/US20240200009A1

## CPC

- C12M 25/14: {Scaffolds; Matrices (in general C12N5/0068)}
- C12M 23/02: {Form or structure of the vessel (large containers B65D88/00)}
- C12M 23/20: {Material Coatings (immunocoatings C12M25/00)}
- C12M 25/18: {Fixed or packed bed}
- C12M 27/18: {Flow directing inserts}
- C12M 29/10: {Perfusion}
- C12M 35/04: {Mechanical means, e.g. sonic waves, stretching forces, pressure or shear stimuli}
- C12N 5/0062: {General methods for three-dimensional culture}
- C12N 5/0634: {Cells from the blood or the immune system}
- C12N 2513/00: 3D culture
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This invention discloses a three-dimensional (3D) bioreactor for large scale expansion of immune cells and methods of use. The 3D bioreactor comprising at least one packed bed chamber comprising at least one porous scaffold; at least one porous scaffold coated with one or more extra cellular matrix protein (ECM); at least one container comprising a fluid media, the fluid media is configured to flow through said packed bed chamber with at least one porous coated scaffold; and at least one population of immune cells suspended in the fluid media, wherein, the at least one porous scaffold coated with said ECM is creates a stationary niche having low shear forces that imitate the natural growth environment of the immune cells and allows expansion of the immune cells population that flow through the coated porous scaffold in large scale.

## Claims

### Claim 1

A three-dimensional (3D) bioreactor for large scale expansion of immune cells, the 3D bioreactor comprising:
at least one packed bed chamber;
at least one porous scaffold surrounded by said at least one packed bed chamber, wherein said at least one porous scaffold is coated with one or more extra cellular matrix protein (ECM);
at least one container surrounding said at least one packed bed chamber; and
a fluid media having at least one population of immune cells suspended in said fluid media contained in said at least one container;
wherein said fluid media having at least one population of immune cells suspended in said fluid media flows through said packed bed chamber and said at least one porous scaffold coated with one or more ECM;
wherein, said at least one porous scaffold coated with one or more ECM creates a stationary niche having low shear forces that imitate the natural growth environment of said population of immune cells;
wherein said at least one porous scaffold coated with one or more ECM has a porosity which allows expansion of the at least one population of immune cells that flow through said at least one porous scaffold coated with one or more ECM in large scale without immobilizing said at least one population of immune cells; and
wherein said immune cells are one of Jurkat, T2 cells, K562 cells, Raji, U937, THP-1, HL-60, Peripheral Blood Mononuclear Cells (PBMC), polymorphonuclear cells (PMN), conventional and unconventional T cells, B cells, B cell Hybridomas, CAR-B, NKT cells, CAR-NKT, gamma-delta T (gdT) cells, CAR-gdT, NK cells, CAR-NK, or combinations thereof.

### Claim 2 (depends on 1)

The 3D bioreactor of claim 1 wherein said PBMC immune cells are unmodified or modified myeloid cells, phagocytosis capable myeloid cells, monocytes, CAR-monocytes, dendritic cells, CAR-dendritic cells, or combinations thereof.

### Claim 3 (depends on 1)

The 3D bioreactor of claim 1 wherein said PMN immune cells are unmodified or modified neutrophils, basophils, eosinophils, or combinations thereof.

### Claim 4 (depends on 1)

The 3D bioreactor of claim 1 wherein said conventional or unconventional T cells immune cells are unmodified or modified T cells consisting of the group: CAR-T, CAR-MAIT, modified T cell receptor (TCR)-T, modified TCR-MAIT, TILs (Tumor Infiltrating Lymphocytes), and combinations thereof.

### Claim 5 (depends on 1)

The 3D bioreactor according to claim 1, wherein said at least one porous scaffold coated with one or more ECM is further coated or linked with at least one immune cell activator.

### Claim 6 (depends on 5)

The 3D bioreactor according to claim 5, wherein said immune cell activator is either one of an Antigen Presenting Cell (APC) either loaded with antigen or unloaded with antigen or an antigen conjugated directly to said at least one porous scaffold coated with one or more ECM.

### Claim 7 (depends on 1)

The 3D bioreactor according to claim 1 wherein said expanded immune cells are further activated within said at least one packed bed chamber upon exposure of said population of immune cells to said at least one porous scaffold coated with one or more ECM coated or linked with at least one immune cell activator.

### Claim 8 (depends on 1)

The 3D bioreactor according to claim 1 wherein said expanded immune cells are further activated within said at least one packed bed chamber upon exposure to a suspended soluble immune cell activator and further expanded with said at least one porous scaffold coated with one or more ECM.

### Claim 9 (depends on 1)

The 3D bioreactor according to claim 1, wherein said at least one population of immune cells are either harvested or reactivated upon exposing an Antigen Presenting Cell (APC) attached to said at least one porous scaffold coated with one or more ECM to an antigen, so as to create additional activation signal to said population of immune cells.

### Claim 10 (depends on 1)

The 3D bioreactor according to claim 1, wherein said at least one population of immune cells are either harvested or reactivated by transferring the expanded immune cells to a different bioreactor comprising at least one porous scaffold coated with a different or similar immune cell activator.

### Claim 11 (depends on 1)

The 3D bioreactor according to claim 1, wherein said at least one porous scaffold coated with one or more ECM is either a single porous scaffold matrix expanded within an inner space of said at least one packed bed chamber, or a plurality of mini or micro porous scaffolds filling said at least one packed bed chamber.

### Claim 12 (depends on 1)

The 3D bioreactor according to claim 1, wherein said fluid media further comprises one or more gene modifying agents capable of genetically modifying said population of immune cells suspended in said fluid media.

### Claim 13 (depends on 12)

The method according to claim 12, further comprising a step of harvesting said immune cell population, or a portion thereof, and further expanding and reactivating said harvested immune cell population either in the same at least one 3D bioreactor or in a different bioreactor.

### Claim 14 (depends on 13)

The method according to claim 13, further comprising a step of harvesting said immune cell population, or a portion thereof, and further expanding and reactivating said harvested immune cell population either in the same at least one 3D bioreactor or in a different bioreactor.

### Claim 15

A method for large scale expansion of immune cells in a three-dimensional (3D) bioreactor, the method comprising the steps of:
a inserting at least one porous scaffold into at least one packed bed chamber;
b. coating said at least one porous scaffold with one or more extra cellular matrix protein (ECM);
c. circulating a fluid media having at least one population of immune cells suspended in said fluid media contained in at least one container surrounding said at least one packed bed chamber, said fluid media having at least one population of immune cells suspended in said fluid media flows through said at least one packed bed chamber and said at least one porous scaffold coated with one or more ECM; and
wherein, said at least one porous scaffold coated with one or more ECM creates a stationary niche having low shear forces that imitate the natural growth environment of said population of immune cells;
wherein said at least one porous scaffold coated with one or more ECM has a porosity which allows expansion of said at least one population of immune cells that flows said at least one porous scaffold coated with one or more ECM in large scale without immobilizing said at least one population of immune cells; and
wherein said immune cells are one of Jurkat, T2 cells, K562 cells, Raji, U973, THP-1, HL-60, Peripheral Blood Mononuclear Cells (PBMC), polymorphonuclear cells (PMN), conventional and unconventional T cells, B cells, B cell Hybridomas, CAR-B, NKT cells, CAR-NKT, gamma-delta T (gdT), CAR-gdT, NK cells, CAR-NK, and combinations thereof.

### Claim 16 (depends on 15)

The method of claim 15 wherein said PBMC immune cells are unmodified or modified myeloid cells, phagocytosis capable myeloid cells, monocytes, CAR-monocytes, dendritic cells, CAR-dendritic cells, and combinations thereof.

### Claim 17 (depends on 15)

The method of claim 15 wherein said conventional or unconventional T-Cell immune cells are unmodified or modified T cells consisting of the group: CAR-T, CAR-MAIT, modified T cell receptor (TCR)-T, modified TCR-MAIT, TILs (Tumor Infiltrating Lymphocytes), and combinations thereof.

### Claim 18 (depends on 15)

The method according to claim 15, further comprising a step of coating said at least one porous scaffold coated with one or more ECM with at least one immune cell activator before or after step b. and, a step of exposing the immune cells population to said at least one activator after step d., so as to expand and activate said population of immune cells within said at least one packed bed chamber.

### Claim 19 (depends on 18)

The method according to claim 18, further comprising a step of genetically modifying said population of immune cells inside said 3D bioreactor by adding to said fluid media one or more gene modifying agents capable of genetically modifying said population of immune cells suspended in said fluid media spiked into said fluid media.

### Claim 20 (depends on 15)

The method according to claim 15, further comprising a step of harvesting said immune cell population, or a portion thereof, and further expanding and reactivating said harvested population of immune cells either in the same at least one 3D bioreactor or in a different bioreactor.

### Claim 21 (depends on 20)

The method according to claim 20, further comprising a step of harvesting said population of immune cells followed by a step of genetically modifying said harvested population of immune cells outside said at least one 3D bioreactor and reseeding said genetically modified harvested population of immune cells into the same at least one 3D bioreactor or in a different bioreactor.

### Claim 22

A three-dimensional (3D) bioreactor for large scale expansion and activation of immune cells population the 3D bioreactor comprising:
at least one packed bed chamber;
at least one porous Antigen Presenting Cell Mimetic Scaffold (APC-MS) surrounded by said at least one packed bed chamber wherein said at least one porous APC-MS is coated with one or more extra cellular matrix protein (ECM);
at least one container surrounding said at least one packed bed chamber; and
a fluid media having at least one population of immune cells suspended in said fluid media contained in said at least one container;
wherein said fluid media having at least one population of immune cells suspended in said fluid media flows through said at least one porous APC-MS coated with one or more ECM;
wherein, said at least one porous APC-MS coated with one or more ECM creates a stationary microenvironment having low shear forces that imitate the natural growth environment of said at least one population of immune cells;
wherein said at least one porous APC-MS coated with one or more ECM has a porosity which allows large scale expansion and/or activation of said at least one population of immune cells that flow through said at least one porous APC-MS coated with one or more ECM without immobilizing said at least one population of immune cells; and
wherein said immune cells are one of Jurkat, T2 cells, K562 cells, Rajii, U973, THP-1, HL-60, Peripheral Blood Mononuclear Cells (PBMC), polymorphonuclear cells (PMN), conventional and unconventional T cells, B cells, B cell Hybridomas, CAR-B, NKT cells, CAR-NKT, gamma-delta T (gdT) cells, CAR-gdT, NK cells, CAR-NK, and combinations thereof.

### Claim 23 (depends on 22)

The 3D bioreactor of claim 22 wherein said PBMC immune cells are unmodified or modified myeloid cells, phagocytosis capable myeloid cells, monocytes, CAR-monocytes, dendritic cells, CAR-dendritic cells, and combinations thereof.

### Claim 24 (depends on 22)

The 3D bioreactor of claim 22 wherein said conventional or unconventional T-cell immune cells are unmodified or modified T cells consisting of the group: CAR-T, CAR-MAIT, modified T cell receptor (TCR)-T, modified TCR-MAIT, TILs (Tumor Infiltrating Lymphocytes), and combinations thereof.

### Claim 25 (depends on 22)

The 3D bioreactor according to claim 22, wherein said at least one porous APC-MS coated with one or more ECM is either a single unit expanded within an inner space of said at least one packed bed chamber, or a plurality of mini/micro porous APC-MS filling said at least one packed bed chamber.
